ATE388164T1 - Tumor-assoziierte peptide, welche an unterschiedliche menschliche leukozytenantigene der klasse ii binden - Google Patents

Tumor-assoziierte peptide, welche an unterschiedliche menschliche leukozytenantigene der klasse ii binden

Info

Publication number: ATE388164T1
Authority: AT; Austria
Prior art keywords: tumour; present; relates; associated peptides; tumor
Prior art date: 2005-09-05

Application number

AT05019254T

Other languages

English (en)

Inventor

Joern Dengjel

Original Assignee

Immatics Biotechnologies Gmbh

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-09-05

Filing date

2005-09-05

Publication date

2008-03-15

2005-09-05 Application filed by Immatics Biotechnologies Gmbh filed Critical Immatics Biotechnologies Gmbh

2008-03-15 Application granted granted Critical

2008-03-15 Publication of ATE388164T1 publication Critical patent/ATE388164T1/de

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
- C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Immunology (AREA)
Organic Chemistry (AREA)
Genetics & Genomics (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Zoology (AREA)
Medicinal Chemistry (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Bioinformatics & Cheminformatics (AREA)
Biophysics (AREA)
Gastroenterology & Hepatology (AREA)
Biomedical Technology (AREA)
Toxicology (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Biotechnology (AREA)
Public Health (AREA)
Cell Biology (AREA)
Wood Science & Technology (AREA)
General Engineering & Computer Science (AREA)
Epidemiology (AREA)
Chemical Kinetics & Catalysis (AREA)
Microbiology (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Physics & Mathematics (AREA)
Plant Pathology (AREA)
Hematology (AREA)
Virology (AREA)
Developmental Biology & Embryology (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

AT05019254T 2005-09-05 2005-09-05 Tumor-assoziierte peptide, welche an unterschiedliche menschliche leukozytenantigene der klasse ii binden ATE388164T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
EP05019254A EP1760088B1 (de)	2005-09-05	2005-09-05	Tumor-assoziierte Peptide, welche an unterschiedliche menschliche Leukozytenantigene der Klasse II binden

Publications (1)

Publication Number	Publication Date
ATE388164T1 true ATE388164T1 (de)	2008-03-15

Family

ID=35170099

Family Applications (5)

Application Number	Title	Priority Date	Filing Date
AT05019254T ATE388164T1 (de)	2005-09-05	2005-09-05	Tumor-assoziierte peptide, welche an unterschiedliche menschliche leukozytenantigene der klasse ii binden
AT07007915T ATE461215T1 (de)	2005-09-05	2005-09-05	Tumor-assoziierte peptide, welche an unterschiedliche menschliche leukozytenantigene der klasse ii binden
AT07007914T ATE461214T1 (de)	2005-09-05	2005-09-05	Tumor-assoziierte peptide, welche an unterschiedliche menschliche leukozytenantigene der klasse ii binden
AT06791838T ATE451388T1 (de)	2005-09-05	2006-09-05	Tumorassoziierte peptide, die promiskuitiv an humane leukozytenantigen- (hla-) moleküle der klasse ii binden
AT09011319T ATE532795T1 (de)	2005-09-05	2006-09-05	Tumor-assoziiertes peptid, welches an unterschiedliche menschliche leukozytenantigene der klasse ii bindet

Family Applications After (4)

Application Number	Title	Priority Date	Filing Date
AT07007915T ATE461215T1 (de)	2005-09-05	2005-09-05	Tumor-assoziierte peptide, welche an unterschiedliche menschliche leukozytenantigene der klasse ii binden
AT07007914T ATE461214T1 (de)	2005-09-05	2005-09-05	Tumor-assoziierte peptide, welche an unterschiedliche menschliche leukozytenantigene der klasse ii binden
AT06791838T ATE451388T1 (de)	2005-09-05	2006-09-05	Tumorassoziierte peptide, die promiskuitiv an humane leukozytenantigen- (hla-) moleküle der klasse ii binden
AT09011319T ATE532795T1 (de)	2005-09-05	2006-09-05	Tumor-assoziiertes peptid, welches an unterschiedliche menschliche leukozytenantigene der klasse ii bindet

Country Status (23)

Country	Link
US (6)	US10196432B2 (de)
EP (6)	EP1806359B1 (de)
JP (1)	JP5627180B2 (de)
KR (3)	KR101386827B1 (de)
CN (3)	CN105440119A (de)
AT (5)	ATE388164T1 (de)
AU (2)	AU2006289290B2 (de)
BR (1)	BRPI0615462A2 (de)
CA (2)	CA2929252A1 (de)
CY (5)	CY1107973T1 (de)
DE (4)	DE602005020046D1 (de)
DK (5)	DK1806359T3 (de)
EA (1)	EA013876B1 (de)
ES (5)	ES2341802T3 (de)
HK (2)	HK1183678A1 (de)
HR (2)	HRP20100128T1 (de)
NO (1)	NO340870B1 (de)
NZ (2)	NZ588813A (de)
PL (5)	PL1806359T3 (de)
PT (5)	PT1806359E (de)
SI (5)	SI1806358T1 (de)
UA (1)	UA98295C2 (de)
WO (1)	WO2007028574A2 (de)

Families Citing this family (92)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ATE388164T1 (de) *	2005-09-05	2008-03-15	Immatics Biotechnologies Gmbh	Tumor-assoziierte peptide, welche an unterschiedliche menschliche leukozytenantigene der klasse ii binden
US20090004213A1 (en) *	2007-03-26	2009-01-01	Immatics Biotechnologies Gmbh	Combination therapy using active immunotherapy
CN103360466B (zh)	2007-07-27	2016-08-03	伊玛提克斯生物技术有限公司	抗肿瘤相关肽及相关抗癌疫苗组合物
ES2555282T3 (es)	2007-07-27	2015-12-30	Immatics Biotechnologies Gmbh	Nuevos epítopos inmunogénicos para inmunoterapia
NZ582824A (en)	2007-07-27	2012-07-27	Immatics Biotechnologies Gmbh	Novel immunotherapy against neuronal and brain tumors
CA2696591C (en) *	2007-08-20	2016-10-11	Oncotherapy Science, Inc.	Cdh3 peptide and medicinal agent comprising the same
CA2704397C (en)	2007-11-01	2018-01-23	Mayo Foundation For Medical Education And Research	Hla-dr binding peptides and their uses
ME02267B (de)	2008-03-27	2016-04-28	Immatics Biotechnologies Gmbh	Neuartige Immuntherapie gegen Nerven- und Hirntumore
DE602008000891D1 (de) *	2008-04-30	2010-05-12	Immatics Biotechnologies Gmbh	Neuartige Formulierungen von Tumor-assoziierten Peptiden, welche an menschliche Leukozytenantigene der Klasse I oder II für Impfungen binden
NO2119726T3 (de)	2008-05-14	2015-05-23
TW201008574A (en)	2008-08-19	2010-03-01	Oncotherapy Science Inc	INHBB epitope peptides and vaccines containing the same
SI2172211T1 (sl) *	2008-10-01	2015-03-31	Immatics Biotechnologies Gmbh	Sestavek s tumorjem povezanih peptidov in zadevnih cepiv proti raku za zdravljenje glioblastoma (GBM) in drugih vrst raka
HUE025795T2 (en) *	2009-01-28	2016-05-30	Ind Tech Res Inst	Urinary and serum biomarkers linked to diabetic nephropathy
US9023802B2 (en)	2009-12-14	2015-05-05	Immatics Biotechnologies Gmbh	HLA-binding peptides derived from prostate-associated antigenic molecules and methods of use thereof
GB201004551D0 (en) *	2010-03-19	2010-05-05	Immatics Biotechnologies Gmbh	NOvel immunotherapy against several tumors including gastrointestinal and gastric cancer
GB201004575D0 (en)	2010-03-19	2010-05-05	Immatics Biotechnologies Gmbh	Composition of tumor associated peptides and related anti cancer vaccine for the treatment of gastric cancer and other cancers
GB201009222D0 (en)	2010-06-02	2010-07-21	Immatics Biotechnologies Gmbh	Improved cancer therapy based on tumour associated antigens derived from cyclin D1
AU2011344652B2 (en)	2010-12-14	2015-11-19	Immatics Biotechnologies Gmbh	HLA-binding peptides derived from prostate-associated antigenic molecules and methods of use thereof
NZ743310A (en) *	2011-03-23	2022-11-25	Fred Hutchinson Cancer Center	Method and compositions for cellular immunotherapy
ES2900004T3 (es)	2013-08-05	2022-03-15	Immatics Biotechnologies Gmbh	Nueva inmunoterapia contra diversos tumores como el cáncer de pulmón, incluido el carcinoma de pulmón amicrocítico (NSCLC)
TWI636065B (zh)	2013-08-05	2018-09-21	伊瑪提克斯生物科技有限公司	新穎肽類，細胞及其用於治療多種腫瘤的用途，其製造方法及包含其等之醫藥組成物
GB201319446D0 (en)	2013-11-04	2013-12-18	Immatics Biotechnologies Gmbh	Personalized immunotherapy against several neuronal and brain tumors
GB201408255D0 (en) *	2014-05-09	2014-06-25	Immatics Biotechnologies Gmbh	Novel immunotherapy against several tumours of the blood, such as acute myeloid leukemia (AML)
IL248203A0 (en)	2014-05-09	2016-11-30	Immatics Biotechnologies Gmbh	Innovative immunotherapy against blood tumors such as acute leukemia in the spinal cord
GB201411037D0 (en)	2014-06-20	2014-08-06	Immatics Biotechnologies Gmbh	Novel immunotherapy against several tumors of the blood, in particular chronic lymphoid leukemai (CLL)
GB201501017D0 (en)	2014-12-23	2015-03-04	Immatics Biotechnologies Gmbh	Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (HCC) and other cancers
HRP20211753T1 (hr)	2014-12-23	2022-04-01	Immatics Biotechnologies Gmbh	Novi peptidi i kombinacije peptida za upotrebu u imunoterapiji protiv hepatocelularnog karcinoma (hcc) i drugih rakova
KR20220167337A (ko)	2015-03-27	2022-12-20	이매틱스 바이오테크놀로지스 게엠베하	다양한 종양에 대한 면역요법에서의 사용을 위한 펩티드 및 펩티드의 조합
GB201505585D0 (en)	2015-03-31	2015-05-13	Immatics Biotechnologies Gmbh	Novel peptides and combination of peptides and scaffolds for use in immunotherapy against renal cell carinoma (RCC) and other cancers
GB201507030D0 (en)	2015-04-24	2015-06-10	Immatics Biotechnologies Gmbh	Immunotherapy against lung cancers, in particular NSCLC
GB201507719D0 (en)	2015-05-06	2015-06-17	Immatics Biotechnologies Gmbh	Novel peptides and combination of peptides and scaffolds thereof for use in immunotherapy against colorectal carcinoma (CRC) and other cancers
NL2014935B1 (en)	2015-06-08	2017-02-03	Applied Immune Tech Ltd	T cell receptor like antibodies having fine specificity.
CR20180040A (es) *	2015-06-19	2018-06-18	Immatics Biotechnologies Gmbh	Nuevos péptidos y nuevas combinaciones de péptidos para el uso en la inmunoterapia y métodos para crear soportes para el uso contra el cáncer de páncreas y otros tipo de cáncer.
GB201511546D0 (en)	2015-07-01	2015-08-12	Immatics Biotechnologies Gmbh	Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
MA54884A (fr) *	2015-07-01	2022-01-12	Immatics Biotechnologies Gmbh	Neuartige peptide und kombination aus peptiden zur verwendung in der immuntherapie gegen ovarialkarzinom und andere karzinome
PE20180259A1 (es)	2015-07-06	2018-02-05	Immatics Biotechnologies Gmbh	Nuevos peptidos y combinacion de peptidos para usar en inmunoterapia contra el cancer esofagico y otros canceres
MY189596A (en)	2015-07-15	2022-02-18	Immatics Biotechnologies Gmbh	A novel peptides for use in immunotherapy against epithelial ovarian cancer and other cancers
GB201513921D0 (en)	2015-08-05	2015-09-23	Immatics Biotechnologies Gmbh	Novel peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers
IL292864A (en)	2015-08-28	2022-07-01	Immatics Biotechnologies Gmbh	New peptides and a combination of peptides and supports for use in immunotherapy in certain types of cancer
MY198087A (en)	2015-10-05	2023-07-31	Immatics Biotechnologies Gmbh	Peptides and combination of peptides for use in immunotherapy against small cell lung cancer and other cancers
MY196837A (en)	2015-12-11	2023-05-03	Immatics Biotechnologies Gmbh	Novel peptides and combination of peptides for use in immunotherapy against various cancers
TWI765875B (zh)	2015-12-16	2022-06-01	美商磨石生物公司	新抗原辨識、製造及用途
GB201522667D0 (en) *	2015-12-22	2016-02-03	Immatics Biotechnologies Gmbh	Novel peptides and combination of peptides for use in immunotherapy against breast cancer and other cancers
GB201602918D0 (en)	2016-02-19	2016-04-06	Immatics Biotechnologies Gmbh	Novel peptides and combination of peptides for use in immunotherapy against NHL and other cancers
MA54832A (fr)	2016-03-01	2021-12-01	Immatics Biotechnologies Gmbh	Peptides, combinaison de peptides et médicaments à base de cellules destinés à être utilisés en immunothérapie contre le cancer de la vessie et d'autres cancers
GB201603568D0 (en) *	2016-03-01	2016-04-13	Immatics Biotechnologies Gmbh	Efficient treatment options including peptides and combination of peptide and cell based medicaments for use in immunotherapy against urinary bladder cancer
GB201603987D0 (en)	2016-03-08	2016-04-20	Immatics Biotechnologies Gmbh	Uterine cancer treatments
KR20220163523A (ko) *	2016-03-31	2022-12-09	바이오엔테크 유에스 인크.	신생항원 및 이것의 사용 방법
CA3020162A1 (en)	2016-04-06	2017-10-12	Immatics Biotechnologies Gmbh	Novel peptides and combination of peptides for use in immunotherapy against aml and other cancers
SG11201808629UA (en) *	2016-04-21	2018-11-29	Immatics Biotechnologies Gmbh	Immunotherapy against melanoma and other cancers
JP2019520038A (ja)	2016-04-21	2019-07-18	イマティクスバイオテクノロジーズゲーエムベーハー	黒色腫およびその他のがんに対する免疫療法
JP7075125B2 (ja)	2016-05-25	2022-05-25	イマティクスバイオテクノロジーズゲーエムベーハー	標的としてのおよび胆嚢がんおよび胆管がんおよびその他のがんに対する免疫療法で使用するための新規ペプチド、ペプチド組み合わせ
RU2630647C1 (ru) *	2016-05-27	2017-09-11	Федеральное государственное унитарное предприятие "Государственный научно-исследовательский институт особо чистых биопрепаратов" Федерального медико-биологического агентства	ГУМАНИЗИРОВАННОЕ АНТИТЕЛО К КОНФОРМАЦИОННОМУ ЭПИТОПУ С3 КОМПОНЕНТА КОМПЛЕМЕНТА ЧЕЛОВЕКА, ПОСЛЕДОВАТЕЛЬНОСТЬ ДНК (ВАРИАНТЫ), ЭКСПРЕССИОННЫЙ ВЕКТОР, СОДЕРЖАЩИЙ ПОСЛЕДОВАТЕЛЬНОСТЬ ДНК (ВАРИАНТЫ), И ШТАММ КЛЕТОК ЯИЧНИКОВ КИТАЙСКОГО ХОМЯЧКА CHO-humC34-ПРОДУЦЕНТ ДАННОГО ГУМАНИЗИРОВАННОГО АНТИТЕЛА
CA3027124A1 (en) *	2016-06-10	2017-12-14	Umc Utrecht Holding B.V.	Novel method for identifying deltat-cell (or gammat-cell) receptor chains or parts thereof that mediate an anti-tumour or an anti-infective response
TW202304970A (zh) *	2016-08-26	2023-02-01	德商英麥提克生物技術股份有限公司	用於頭頸鱗狀細胞癌和其他癌症免疫治療的新型肽和支架
KR102379955B1 (ko)	2016-12-08	2022-03-29	이매틱스 바이오테크놀로지스 게엠베하	짝짓기가 향상된 t 세포 수용체
DE102016123893A1 (de)	2016-12-08	2018-06-14	Immatics Biotechnologies Gmbh	T-Zellrezeptoren mit verbesserter Bindung
AR110857A1 (es)	2017-01-27	2019-05-08	Immatics Biotechnologies Gmbh	Péptidos y combinaciones de péptidos para el uso en la inmunoterapia contra el cáncer de ovario y otros tipos de cáncer
MX2019008843A (es)	2017-01-27	2019-12-09	Immatics Biotechnologies Gmbh	Peptidos novedosos y combinaciones de peptidos para el uso de la inmunoterapia contra el cancer de ovario y otros tipos de cancer.
MA47367B1 (fr)	2017-01-27	2023-06-28	Immatics Biotechnologies Gmbh	Nouveaux peptides et combinaison de peptides à utiliser en immunothérapie contre le cancer de l'ovaire et d'autres cancers
EP3576767A4 (de) *	2017-02-06	2020-12-02	Academia Sinica	Rekombinante proteine und verwendungen davon
MX2019012225A (es)	2017-04-10	2019-12-09	Immatics Biotechnologies Gmbh	Peptidos y combinaciones de los mismos para el uso en la inmunoterapia contra diversos tipos de cancer.
US11427614B2 (en)	2017-04-10	2022-08-30	Immatics Biotechnologies Gmbh	Peptides and combination thereof for use in the immunotherapy against cancers
WO2018189152A2 (en)	2017-04-10	2018-10-18	Immatics Biotechnologies Gmbh	Peptides and combination of peptides for use in immunotherapy against leukemias and other cancers
CN110944660A (zh)	2017-04-10	2020-03-31	伊玛提克斯生物技术有限公司	用于白血病和其他癌症免疫治疗的肽和肽组合物
WO2019007974A1 (en)	2017-07-07	2019-01-10	Immatics Biotechnologies Gmbh	NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY OF LUNG CANCER, INCLUDING NSCLC, CPPC AND OTHER CANCERS
SG11201913302SA (en)	2017-07-07	2020-01-30	Immatics Biotechnologies Gmbh	Novel peptides and combination of peptides for use in immunotherapy against lung cancer, including nsclc, sclc and other cancers
CN111093391A (zh)	2017-09-18	2020-05-01	S&P 配料研发有限公司	含氯化钾的低钠食盐代用品
WO2019075112A1 (en)	2017-10-10	2019-04-18	Gritstone Oncology, Inc.	IDENTIFICATION OF NEO-ANTIGENS USING HOT POINTS
CA3083097A1 (en)	2017-11-22	2019-05-31	Gritstone Oncology, Inc.	Reducing junction epitope presentation for neoantigens
DE102018108996B4 (de)	2018-02-09	2021-10-21	Immatics US, Inc.	Verfahren zur Herstellung autologer T-Zellen
WO2019157298A1 (en)	2018-02-09	2019-08-15	Immatics US, Inc.	Methods for manufacturing t cells
DE102018107224A1 (de)	2018-02-21	2019-08-22	Immatics Biotechnologies Gmbh	Peptide und Kombinationen von Peptiden nicht-kanonischen Ursprungs zur Verwendung in der Immuntherapie gegen verschiedene Krebsarten
EP3759131A4 (de) *	2018-02-27	2021-12-01	Gritstone bio, Inc.	Neoantigen-identifizierung mit pan-allelmodellen
EP3539562A1 (de) *	2018-03-12	2019-09-18	Eberhard Karls Universität Tübingen Medizinische Fakultät	Immuntherapeutische peptide
TW202016131A (zh)	2018-05-16	2020-05-01	德商英麥提克生物技術股份有限公司	用於抗癌免疫治療的肽
US10925947B2 (en)	2018-06-29	2021-02-23	Immatics Biotechnologies Gmbh	A*03 restricted peptides for use in immunotherapy against cancers and related methods
TW202019955A (zh)	2018-07-31	2020-06-01	德商英麥提克生物技術股份有限公司	B*07 限制肽和肽組合的抗癌免疫治療和相關方法
TW202028224A (zh)	2018-09-17	2020-08-01	德商英麥提克生物技術股份有限公司	B*44限制肽在抗癌免疫治療的用途和相關方法
TW202024121A (zh)	2018-09-18	2020-07-01	德商英麥提克生物技術股份有限公司	A*01 限制肽和肽組合物在抗癌免疫治療中的用途和相關方法
TW202039535A (zh)	2018-12-18	2020-11-01	德商英麥提克生物技術股份有限公司	B*08限制肽和肽組合物抗癌免疫治療和相關方法
KR102215578B1 (ko) *	2019-03-28	2021-02-15	한국과학기술연구원	인간 백혈구 항원에 특이적으로 결합하는 펩타이드 및 이의 용도
JP2022535421A (ja)	2019-06-06	2022-08-08	イマティクスバイオテクノロジーズゲーエムベーハー	配列類似ペプチドを使用した対抗選択による選別
CN110305209B (zh) *	2019-07-09	2022-09-13	福建医科大学附属第一医院	用于治疗恶性肿瘤的多肽及其作为疫苗的用途
JP2022543059A (ja) *	2019-07-30	2022-10-07	ユニバーシティーヘルスネットワーク	Ｔ細胞受容体及びその使用方法
EP3827840A1 (de) *	2019-11-29	2021-06-02	Academisch Ziekenhuis Leiden h.o.d.n. LUMC	Teipp-peptid-variante und verwendungen davon
DE102020125465A1 (de)	2020-09-29	2022-03-31	Immatics Biotechnologies Gmbh	Amidierte Peptide und ihre deamidierten Gegenstücke, die durch nicht-HLA-A*02-Moleküle präsentiert werden, zur Verwendung in der Immuntherapie gegen verschiedene Krebsarten
US11891427B2 (en)	2020-09-29	2024-02-06	Immatics Biotechnologies Gmbh	Amidated peptides and their deamidated counterparts displayed by non-HLA-a*02 for use in immunotherapy against different types of cancers
DE102020125457A1 (de)	2020-09-29	2022-03-31	Immatics Biotechnologies Gmbh	Amidierte Peptide und ihre deamidierten Gegenstücke, die durch HLA-A*02-Moleküle präsentiert werden, zur Verwendung in der Immuntherapie gegen verschiedene Krebsarten
TW202241925A (zh)	2021-01-15	2022-11-01	德商英麥提克生物技術股份有限公司	用於不同類型癌症免疫治療的ｈｌａ展示肽
WO2024077601A1 (en) *	2022-10-14	2024-04-18	Guangdong Tcrcure Biopharma Technology Co., Ltd.	Peptide vaccines against glioma and uses thereof
CN117720620B (zh) *	2023-12-13	2024-07-23	无锡市儿童医院	小分子多肽和其药物组合物、其制药用途

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US8258260B2 (en) *	1970-02-11	2012-09-04	Immatics Biotechnologies Gmbh	Tumor-associated peptides binding promiscuously to human leukocyte antigen (HLA) class II molecules
US8212000B2 (en) *	1970-02-11	2012-07-03	Immatics Biotechnologies Gmbh	Tumor-associated peptides binding promiscuously to human leukocyte antigen (HLA) class II molecules
US8211999B2 (en) *	1970-02-11	2012-07-03	Immatics Biotechnologies Gmbh	Tumor-associated peptides binding promiscuously to human leukocyte antigen (HLA) class II molecules
US4440859A (en)	1977-05-27	1984-04-03	The Regents Of The University Of California	Method for producing recombinant bacterial plasmids containing the coding sequences of higher organisms
GR66050B (de) *	1977-09-20	1981-01-14	Licinvest Ag
US4704362A (en)	1977-11-08	1987-11-03	Genentech, Inc.	Recombinant cloning vehicle microbial polypeptide expression
IN151589B (de)	1978-12-22	1983-05-28	Biogen Nv
US4530901A (en)	1980-01-08	1985-07-23	Biogen N.V.	Recombinant DNA molecules and their use in producing human interferon-like polypeptides
US4678751A (en)	1981-09-25	1987-07-07	Genentech, Inc.	Hybrid human leukocyte interferons
US4766075A (en)	1982-07-14	1988-08-23	Genentech, Inc.	Human tissue plasminogen activator
US4582800A (en)	1982-07-12	1986-04-15	Hoffmann-La Roche Inc.	Novel vectors and method for controlling interferon expression
US4757006A (en)	1983-10-28	1988-07-12	Genetics Institute, Inc.	Human factor VIII:C gene and recombinant methods for production
US4677063A (en)	1985-05-02	1987-06-30	Cetus Corporation	Human tumor necrosis factor
US4810648A (en)	1986-01-08	1989-03-07	Rhone Poulenc Agrochimie	Haloarylnitrile degrading gene, its use, and cells containing the gene
US4810781A (en)	1987-01-15	1989-03-07	The George Washington University	Methods of preparing epitopes of tumor associated antigens
CA2132859A1 (en) *	1992-04-03	1993-10-14	Michael D. Pierschbacher	Decorin fragments and methods of inhibiting cell regulatory factors
DE69332485T2 (de) *	1992-08-11	2003-11-13	The President And Fellows Of Harvard College, Cambridge	Immunmodulierende peptide
CA2175380A1 (en) *	1993-10-29	1995-05-04	Lan Bo Chen	A novel tumor marker and novel method of isolating same
AUPM322393A0 (en)	1993-12-24	1994-01-27	Austin Research Institute, The	Mucin carbohydrate compounds and their use in immunotherapy
WO1996003144A1 (en)	1994-07-27	1996-02-08	The Council Of The Queensland Institute Of Medical Research	Polyepitope vaccines
UY24367A1 (es) *	1995-11-23	2000-10-31	Boehringer Ingelheim Int	Vacunas contra tumores y procedimiento para su produccion
PT879282E (pt)	1996-01-17	2003-11-28	Imp College Innovations Ltd	Imunoterapia utilizando linfocitos t citotoxicos (ctl)
US6610821B1 (en) *	1996-07-12	2003-08-26	Mcgill University	Compounds and methods for modulating endothelial cell adhesion
EP0988385A2 (de) *	1997-01-21	2000-03-29	Human Genome Sciences	Polypeptide, die tace und matrilysin ähneln.
US6316213B1 (en) *	1997-03-19	2001-11-13	The Board Of Trustees Of The University Of Arkansas	Methods for the early diagnosis of ovarian, breast and lung cancer
ES2245048T3 (es)	1997-10-15	2005-12-16	Pharis Biotec Gmbh	Factor de crecimiento derivado de cadherina y su uso.
DE19757250A1 (de) *	1997-12-22	1999-07-01	Forssmann Wolf Georg Prof Dr	Insulin-like growth factor binding protein und seine Verwendung
US6746852B1 (en) *	1998-05-08	2004-06-08	Osi Pharmaceuticals, Inc.	AGS proteins and nucleic acid molecules and uses thereof
DE19936563A1 (de)	1999-08-04	2001-02-08	Boehringer Ingelheim Int	Tumorassoziiertes Antigen
DE19938583A1 (de)	1999-08-18	2001-02-22	Buehler Ag	Verfahren und Vorrichtung zur Herstellung von kristallisationsfähigem Kunststoffmaterial
GB2373500B (en) *	2000-02-04	2004-12-15	Aeomica Inc	Methods and apparatus for predicting, confirming, and displaying functional information derived from genomic sequence
WO2002008765A2 (en) *	2000-07-26	2002-01-31	Stanford University	Basal cell markers in breast cancer and uses thereof
WO2002050103A2 (en)	2000-12-20	2002-06-27	Glaxosmithkline Biologicals S.A.	Tumour-related antigens
AU2002303219A1 (en) *	2001-03-30	2002-10-15	Corixa Corporation	Compositions and methods for the therapy and diagnosis of cancer
US6867283B2 (en)	2001-05-16	2005-03-15	Technion Research & Development Foundation Ltd.	Peptides capable of binding to MHC molecules, cells presenting such peptides, and pharmaceutical compositions comprising such peptides and/or cells
US7049413B2 (en) *	2001-05-18	2006-05-23	Ludwig Institute For Cancer Research	MAGE-A3 peptides presented by HLA class II molecules
AU2002322280A1 (en) *	2001-06-21	2003-01-21	Millennium Pharmaceuticals, Inc.	Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
AU2002323120A1 (en) *	2001-08-13	2003-03-03	Dana-Farber Cancer Institute, Inc.	Periostin-based diagnostic assays
US6906036B2 (en) *	2001-08-16	2005-06-14	Kimberly-Clark Worldwide, Inc.	Anti-aging and wound healing compounds
WO2003030836A2 (en) *	2001-10-12	2003-04-17	Case Western Reserve University	Neuronal regeneration
AU2003215244A1 (en) *	2002-02-14	2003-09-04	Curagen Corporation	Complexes and methods of using same
US20030194704A1 (en) *	2002-04-03	2003-10-16	Penn Sharron Gaynor	Human genome-derived single exon nucleic acid probes useful for gene expression analysis two
AU2002368151A1 (en) *	2002-08-13	2004-02-25	Warner-Lambert Company Llc	Matrix metalloproteinase inhibitors and methods for identification of lead compounds
CA2500687A1 (en) *	2002-10-02	2004-04-15	Genentech, Inc.	Compositions and methods for the diagnosis and treatment of tumor
WO2004110345A2 (en) *	2002-10-29	2004-12-23	Pharmacia Corporation	Differentially expressed genes involved in cancer, the polypeptides encoded thereby, and methods of using the same
WO2004106495A2 (en) *	2003-05-29	2004-12-09	Millennium Pharmaceuticals, Inc.	Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
US20080227125A1 (en) *	2003-07-15	2008-09-18	Guilaine Argoud-Puy	Secreted Polypeptide Species Reduced in Cardiovascular Disorders
EP1757940A1 (de)	2005-08-26	2007-02-28	Cézanne S.A.S.	In vitro Methode zur Diagnose und zum Monitoring von Nierenzellkarzinom unter Verwendung von MMP-7 als humoraler Biomarker für Nierenzellkarzinom
ATE388164T1 (de) *	2005-09-05	2008-03-15	Immatics Biotechnologies Gmbh	Tumor-assoziierte peptide, welche an unterschiedliche menschliche leukozytenantigene der klasse ii binden
EP1760089B1 (de) *	2005-09-05	2009-08-19	Immatics Biotechnologies GmbH	Tumorassoziierte Peptide, die HLA Klasse I oder II-Moleküle binden, und anti-Tumor Impfstoffe
EP1795599A1 (de) *	2005-12-09	2007-06-13	Schuler, Gerold, Prof. Dr.	Verfahren zur Herstellung Antigen-spezifischer Effektor T-Zellen

2005
- 2005-09-05 AT AT05019254T patent/ATE388164T1/de active
- 2005-09-05 DK DK07007915.7T patent/DK1806359T3/da active
- 2005-09-05 DK DK05019254T patent/DK1760088T3/da active
- 2005-09-05 DE DE602005020046T patent/DE602005020046D1/de active Active
- 2005-09-05 PL PL07007915T patent/PL1806359T3/pl unknown
- 2005-09-05 DE DE602005020047T patent/DE602005020047D1/de active Active
- 2005-09-05 PT PT07007915T patent/PT1806359E/pt unknown
- 2005-09-05 PL PL05019254T patent/PL1760088T3/pl unknown
- 2005-09-05 SI SI200531005T patent/SI1806358T1/sl unknown
- 2005-09-05 EP EP07007915A patent/EP1806359B1/de not_active Not-in-force
- 2005-09-05 SI SI200530994T patent/SI1806359T1/sl unknown
- 2005-09-05 AT AT07007915T patent/ATE461215T1/de active
- 2005-09-05 EP EP07007914A patent/EP1806358B1/de not_active Not-in-force
- 2005-09-05 PT PT05019254T patent/PT1760088E/pt unknown
- 2005-09-05 DK DK07007914.0T patent/DK1806358T3/da active
- 2005-09-05 ES ES07007914T patent/ES2341802T3/es active Active
- 2005-09-05 EP EP05019254A patent/EP1760088B1/de not_active Not-in-force
- 2005-09-05 PT PT07007914T patent/PT1806358E/pt unknown
- 2005-09-05 ES ES05019254T patent/ES2302546T3/es active Active
- 2005-09-05 PL PL07007914T patent/PL1806358T3/pl unknown
- 2005-09-05 SI SI200530167T patent/SI1760088T1/sl unknown
- 2005-09-05 AT AT07007914T patent/ATE461214T1/de active
- 2005-09-05 DE DE602005005196T patent/DE602005005196T2/de active Active
- 2005-09-05 ES ES07007915T patent/ES2341295T3/es active Active
2006
- 2006-09-05 KR KR1020137002915A patent/KR101386827B1/ko not_active IP Right Cessation
- 2006-09-05 WO PCT/EP2006/008642 patent/WO2007028574A2/en active Application Filing
- 2006-09-05 DK DK06791838.3T patent/DK1922335T3/da active
- 2006-09-05 AT AT06791838T patent/ATE451388T1/de active
- 2006-09-05 NZ NZ588813A patent/NZ588813A/en not_active IP Right Cessation
- 2006-09-05 PL PL06791838T patent/PL1922335T3/pl unknown
- 2006-09-05 SI SI200631206T patent/SI2135878T1/sl unknown
- 2006-09-05 CN CN201510571930.7A patent/CN105440119A/zh active Pending
- 2006-09-05 EP EP06791838A patent/EP1922335B1/de active Active
- 2006-09-05 NZ NZ566104A patent/NZ566104A/en not_active IP Right Cessation
- 2006-09-05 SI SI200630566T patent/SI1922335T1/sl unknown
- 2006-09-05 KR KR1020137002917A patent/KR101386790B1/ko not_active IP Right Cessation
- 2006-09-05 AT AT09011319T patent/ATE532795T1/de active
- 2006-09-05 ES ES09011319T patent/ES2373907T3/es active Active
- 2006-09-05 DE DE602006011030T patent/DE602006011030D1/de active Active
- 2006-09-05 CA CA2929252A patent/CA2929252A1/en not_active Abandoned
- 2006-09-05 PL PL09011319T patent/PL2135878T3/pl unknown
- 2006-09-05 EA EA200800677A patent/EA013876B1/ru not_active IP Right Cessation
- 2006-09-05 US US11/912,670 patent/US10196432B2/en active Active
- 2006-09-05 KR KR1020087008073A patent/KR101386355B1/ko not_active IP Right Cessation
- 2006-09-05 AU AU2006289290A patent/AU2006289290B2/en not_active Ceased
- 2006-09-05 JP JP2008528438A patent/JP5627180B2/ja not_active Expired - Fee Related
- 2006-09-05 DK DK09011319.2T patent/DK2135878T3/da active
- 2006-09-05 CA CA2621389A patent/CA2621389C/en not_active Expired - Fee Related
- 2006-09-05 CN CN2006800383657A patent/CN101287754B/zh not_active Expired - Fee Related
- 2006-09-05 CN CN201210560635.8A patent/CN103059104B/zh not_active Expired - Fee Related
- 2006-09-05 PT PT06791838T patent/PT1922335E/pt unknown
- 2006-09-05 BR BRPI0615462-0A patent/BRPI0615462A2/pt not_active Application Discontinuation
- 2006-09-05 EP EP09011317A patent/EP2138509A1/de not_active Withdrawn
- 2006-09-05 PT PT09011319T patent/PT2135878E/pt unknown
- 2006-09-05 UA UAA200803825A patent/UA98295C2/ru unknown
- 2006-09-05 EP EP09011319A patent/EP2135878B1/de active Active
- 2006-09-05 ES ES06791838T patent/ES2337399T3/es active Active
2007
- 2007-11-19 US US11/942,573 patent/US7807642B2/en active Active
- 2007-11-19 US US11/942,394 patent/US20080206216A1/en not_active Abandoned
- 2007-11-19 US US11/942,598 patent/US7833969B2/en active Active
- 2007-11-19 US US11/942,620 patent/US7833970B2/en active Active
2008
- 2008-04-04 NO NO20081683A patent/NO340870B1/no not_active IP Right Cessation
- 2008-05-28 CY CY20081100554T patent/CY1107973T1/el unknown
2010
- 2010-02-19 CY CY20101100169T patent/CY1109849T1/el unknown
- 2010-03-09 HR HR20100128T patent/HRP20100128T1/hr unknown
- 2010-05-27 CY CY20101100469T patent/CY1110051T1/el unknown
- 2010-06-11 CY CY20101100520T patent/CY1110187T1/el unknown
- 2010-10-26 AU AU2010236029A patent/AU2010236029B2/en not_active Ceased
2011
- 2011-12-09 CY CY20111101223T patent/CY1112186T1/el unknown
- 2011-12-30 HR HR20110981T patent/HRP20110981T1/hr unknown
2013
- 2013-10-02 HK HK13111197.3A patent/HK1183678A1/xx not_active IP Right Cessation
2015
- 2015-11-05 US US14/933,077 patent/US10618945B2/en active Active
2016
- 2016-07-26 HK HK16108913.9A patent/HK1220709A1/zh unknown

Also Published As

Publication number	Publication date
ES2341802T3 (es)	2010-06-28
EP1806358A3 (de)	2007-10-03
EA200800677A1 (ru)	2008-08-29
ATE451388T1 (de)	2009-12-15
KR101386355B1 (ko)	2014-04-17
PT2135878E (pt)	2012-01-05
CN103059104A (zh)	2013-04-24
PT1806358E (pt)	2010-05-28
EP1806358B1 (de)	2010-03-17
EP1760088A1 (de)	2007-03-07
AU2010236029B2 (en)	2012-06-28
PL2135878T3 (pl)	2012-06-29
HRP20100128T1 (hr)	2010-04-30
US10196432B2 (en)	2019-02-05
PL1922335T3 (pl)	2010-05-31
NZ588813A (en)	2011-06-30
WO2007028574A3 (en)	2007-05-24
US20160115212A1 (en)	2016-04-28
US20080206216A1 (en)	2008-08-28
WO2007028574A2 (en)	2007-03-15
AU2006289290B2 (en)	2010-11-25
CY1109849T1 (el)	2014-09-10
US20080207520A1 (en)	2008-08-28
DE602005020046D1 (de)	2010-04-29
EP1760088B1 (de)	2008-03-05
US10618945B2 (en)	2020-04-14
DK1760088T3 (da)	2008-06-09
CY1110187T1 (el)	2015-01-14
DE602005005196D1 (de)	2008-04-17
EA013876B1 (ru)	2010-08-30
HK1220709A1 (zh)	2017-05-12
EP1922335A2 (de)	2008-05-21
JP5627180B2 (ja)	2014-11-19
CA2621389A1 (en)	2007-03-15
ES2337399T3 (es)	2010-04-23
US7807642B2 (en)	2010-10-05
NZ566104A (en)	2011-04-29
AU2010236029A1 (en)	2010-11-18
KR20080052643A (ko)	2008-06-11
CA2929252A1 (en)	2007-03-15
NO340870B1 (no)	2017-07-03
BRPI0615462A2 (pt)	2011-05-17
CN105440119A (zh)	2016-03-30
SI1806358T1 (sl)	2010-06-30
EP2138509A1 (de)	2009-12-30
CY1112186T1 (el)	2015-12-09
EP1806358A2 (de)	2007-07-11
SI1806359T1 (sl)	2010-06-30
HRP20110981T1 (hr)	2012-02-29
JP2010502173A (ja)	2010-01-28
EP2135878A1 (de)	2009-12-23
DK1806358T3 (da)	2010-06-28
PL1760088T3 (pl)	2008-10-31
PL1806359T3 (pl)	2010-08-31
NO20081683L (no)	2008-04-04
CY1107973T1 (el)	2013-09-04
EP1806359B1 (de)	2010-03-17
DK2135878T3 (da)	2012-02-27
SI1760088T1 (sl)	2008-06-30
EP1922335B1 (de)	2009-12-09
PT1760088E (pt)	2008-05-14
WO2007028574A9 (en)	2008-05-02
CN101287754B (zh)	2013-02-13
ATE532795T1 (de)	2011-11-15
DE602005005196T2 (de)	2008-06-26
CN103059104B (zh)	2015-10-28
KR20130019033A (ko)	2013-02-25
DE602006011030D1 (de)	2010-01-21
US7833970B2 (en)	2010-11-16
DE602005020047D1 (de)	2010-04-29
US20080206218A1 (en)	2008-08-28
KR20130019034A (ko)	2013-02-25
DK1806359T3 (da)	2010-06-14
KR101386790B1 (ko)	2014-04-21
HK1183678A1 (en)	2014-01-03
CN101287754A (zh)	2008-10-15
ATE461214T1 (de)	2010-04-15
PT1806359E (pt)	2010-05-25
CY1110051T1 (el)	2015-01-14
SI2135878T1 (sl)	2012-03-30
CA2621389C (en)	2016-07-19
DK1922335T3 (da)	2010-04-19
US7833969B2 (en)	2010-11-16
US20080206217A1 (en)	2008-08-28
UA98295C2 (ru)	2012-05-10
EP2135878B1 (de)	2011-11-09
SI1922335T1 (sl)	2010-04-30
KR101386827B1 (ko)	2014-04-17
PL1806358T3 (pl)	2010-08-31
US20100040590A1 (en)	2010-02-18
PT1922335E (pt)	2010-03-03
ES2302546T3 (es)	2008-07-16
EP1806359A1 (de)	2007-07-11
ES2373907T3 (es)	2012-02-10
ATE461215T1 (de)	2010-04-15
AU2006289290A1 (en)	2007-03-15
ES2341295T3 (es)	2010-06-17

Legal Events

Date

Code

Title

Description

2008-10-15

UEP

Publication of translation of european patent specification

Ref document number: 1760088

Country of ref document: EP